Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Emerging Diseases: Disruptive, Commercially Risky, But GSK Has A Solution

Executive Summary

GlaxoSmithKline PLC has offered up its new Maryland vaccine research and development center, and its scientists, under the company's proposal to establish a global collaboration for the pursuit of products that are commercially risky, but necessary to address emerging infectious diseases, before a public health crisis strikes.

Advertisement

Related Content

Playing the Long Game, Partnerships Required For Emerging Infectious Diseases
GSK/NIH 'SAM' Strategy May Reap Benefits Beyond Zika
Fauci: Borrowed Cash Won't Carry Zika Efficacy Trials
Congrats, Your Vaccine Works; Now, Who Will Buy It?
GSK to set up global vaccine center near FDA, NIH
Bill Gates: Infectious disease must be attacked like war
US Capitol Capsule: Ebola crisis spurs vows to boost global health security

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel